"The candidate, dubbed Effi-7, is an immunomodulatory monoclonal antibody that targets the primary chain of the interleukin-7 receptor, a protein found on the surface of cells. It works by inhibiting the IL-7 receptor and the internalization of the receptor. In vitro studies have shown that this prompts an antagonistic effect on T cells, which are implicated in autoimmune disease, according to a statement."
"When you take Lodonal at bedtime, it attaches to opioid receptors in the brain and in all types of immune cells, which temporarily blocks endorphins from attaching to them. This signals your body to increase endorphin production. The increased endorphin production helps orchestrate the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells. It also prevents immune system overactivity, which is the crux of autoimmune disorders, and blunts the release of inflammatory and neurotoxic chemicals in the brain."
Lodonal and Effi-7 are both new drugs to the market. Lodonal is an off label prescription from its FDA approved parent drug of Naltrexone. Lodonal has been around for a while but it is finally getting the funding it needs to get FDA approval and go through trials. Both Effi-7 and Lodonal have a profound effect on T cells. Lodonal is also very active with B cells, natural kilelrs cells and more. Lodonal is not limited to autoimmune diseases but works on cancer, weightloss, and antiaging. The only side effect ever reported is slight sleep distrubance the first few weeks of taking Lodonal but that is rare. Effi-7 is too new to know the full range of side effects it may or may not cause.